A New mRNA Flu Shot Is Now Available for Adults 50 and Older
Finn's Take· TL;DR- mRNA flu vaccine approved for adults 50+ offers 26.6% better protection than standard flu shots by generating broader immune response.
- Older adults face severe flu risk: seniors comprise 71% of seasonal deaths; new vaccine targets immunosenescence affecting aging immune systems.
- Rollout underway at major pharmacies; Medicare coverage confirmed for 65+, but private insurance coverage for 50-64 age group unclear.
A Familiar Technology, A New Flu Fighter
The FDA has approved mFLUSIVA (mRNA-1010), Moderna's mRNA-based influenza vaccine, for use in adults 50 and older. The shot uses the same platform that powered COVID-19 vaccines — and researchers say it's a meaningful leap forward in how we protect older adults from one of the season's most dangerous respiratory threats.
Adults 50 and older are eligible for the new mRNA flu vaccine, developed using the same technology as COVID-19 vaccines. It will protect against seasonal flu, but also help generate immunity against other parts of the flu virus that don't change, said Deborah Fuller, a professor of microbiology at the University of Washington School of Medicine. Fuller added that the mRNA vaccine can produce antibodies that recognize a broader range of influenza viruses and train certain white blood cells to provide another layer of immune protection.
Why This Age Group Needs Better Protection
According to Dr. Fuller, "Anybody over 50, their immune system undergoes what we call 'immunosenescence'; it starts to get old, and it doesn't respond as well to vaccines as we did when we were young." That biological reality has long made influenza especially dangerous for this population — and it's exactly what this new vaccine was designed to address.
Adults 65 and older comprise 57% of hospitalizations and 71% of deaths in a typical U.S. flu season. The stakes are real. Last flu season, 253 flu-related deaths were recorded in Washington state alone. In the season prior, 2024–25, Washington saw 508 flu deaths. A vaccine that meaningfully reduces those numbers could save thousands of lives nationwide each year.
How Much Better Does It Actually Work?
mFLUSIVA demonstrated a relative vaccine efficacy of 26.6% against lab-confirmed influenza compared to a standard-dose comparator, meeting prespecified superiority criteria. Put simply, the new shot is almost 30% more effective than the traditional vaccine for older adults at higher risk of hospitalization or death.
Approval in adults aged 50 to 64 was supported by a Phase 3 trial involving 40,805 adults aged 50 and older across 11 countries. Laboratory-confirmed influenza-like illness occurred in 2.0% of mFLUSIVA recipients versus 2.8% of those receiving a standard-dose influenza vaccine. There is one trade-off worth knowing: solicited adverse reactions within 7 days of vaccination were more frequently reported with mFLUSIVA than with the standard-dose comparator, though most reactions were mild, moderate, transient, and self-limiting.
Where to Get It and What to Know
mFLUSIVA is being rolled out to pharmacies like CVS and Walgreens, though not every local pharmacy is expected to have the shot available yet. Adults 65 and older are likely to have the new mRNA flu vaccine covered under Medicare plans, while it remains unclear which private insurance companies will cover the new shot for adults between 50 and 64 years old.
Fuller recommends anyone over the age of 50 talk with their doctor or pharmacist before getting the new vaccine, especially if they had a severe reaction to the COVID-19 mRNA vaccine. Beyond that, her message is straightforward: "Having a vaccine is better than not having a vaccine — and mRNA vaccines are safe, they are effective, they have been proven." The broader significance of mFLUSIVA may be as a new way to develop and update seasonal flu vaccines — an advantage that will become clearer as effectiveness is evaluated across multiple influenza seasons.